AI-Designed Antibodies Work Inside Cells to Fight Dementia

Scientists at the University of Essex have created microscopic medicines that can work inside human cells, opening new paths to treat devastating brain diseases like Alzheimer's and Parkinson's.

Traditional antibodies have always faced one major problem. They work great outside cells but fall apart inside them, making it impossible to target the disease-causing proteins where they actually do their damage.

Dr. Caitlin O'Shea and Dr. Gareth Wright led an international team that figured out why. After analyzing millions of antibodies, they discovered the issue was electrical charge.

Regular antibodies have the wrong charge to survive inside cells without clumping together. Using AI software developed by Nobel Prize winner David Baker, the team redesigned 672 antibodies to have the right charge and stability.

These new "intrabodies" can now be produced inside human cells and attach directly to proteins linked to neurodegenerative diseases. They target the problem at its source, where these conditions actually begin.

The team specifically designed intrabodies to stick to proteins that cause Alzheimer's, Parkinson's, Huntington's, and motor neuron disease. These conditions lead to memory loss, muscle control problems, and currently have no cures.

The researchers published their findings in Nature Communications and made all 672 redesigned molecules publicly available. This means scientists worldwide can now use them as research tools or starting points for new therapies.

Why This Inspires

This breakthrough turns decades of antibody research into something entirely new. Scientists have spent years developing antibodies that work outside cells, and now those same molecules can be adapted to work inside them too.

The MND Association, which funded the research, called it a significant advance. Dr. Brian Dickie, Chief Scientist at the charity, said combining this intrabody science with emerging gene therapy techniques could create new therapeutic strategies that hit specific targets inside neurons.

Over one million people in the UK alone live with neurodegenerative diseases. For families watching loved ones lose memories or muscle control, this research offers genuine hope that treatments might finally target these diseases where they start.

The work represents more than just clever engineering. It shows how AI can solve problems that have stumped scientists for years, turning impossible challenges into real solutions that could change lives.